Adma Biologics Inc (NASDAQ: ADMA) closed the day trading at $6.11 down -1.77% from the previous closing price of $6.22. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 2205281 shares were traded.
Ratios:
For a better understanding of ADMA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 27.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 346.01. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 1.05 whereas as Long-Term Debt/Eq ratio is at 1.04.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 19 ’24 when ELMS STEVE sold 411,829 shares for $6.08 per share. The transaction valued at 2,503,920 led to the insider holds 2,115,671 shares of the business.
ELMS STEVE sold 49,887 shares of ADMA for $299,821 on Mar 18 ’24. The Director now owns 2,527,500 shares after completing the transaction at $6.01 per share. On Mar 15 ’24, another insider, ELMS STEVE, who serves as the Director of the company, sold 183,008 shares for $6.01 each. As a result, the insider received 1,099,878 and left with 2,577,387 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 1.39B and an Enterprise Value of 1.48B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.40 while its Price-to-Book (P/B) ratio in mrq is 10.22. Its current Enterprise Value per Revenue stands at 5.75 whereas that against EBITDA is 289.94.
Stock Price History:
Over the past 52 weeks, ADMA has reached a high of $6.76, while it has fallen to a 52-week low of $3.06. The 50-Day Moving Average of the stock is 5.79, while the 200-Day Moving Average is calculated to be 4.38.
Shares Statistics:
Over the past 3-months, ADMA traded about 2.74M shares per day on average, while over the past 10 days, ADMA traded about 2.49M shares per day. A total of 226.06M shares are outstanding, with a floating share count of 219.42M. Insiders hold about 3.86% of the company’s shares, while institutions hold 74.29% stake in the company. Shares short for ADMA as of Mar 15, 2024 were 7.99M with a Short Ratio of 2.92, compared to 6.15M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.50% and a Short% of Float of 3.67%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.07 and a low estimate of $0.05, while EPS last year was -$0.03. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.32 and $0.28 for the fiscal current year, implying an average EPS of $0.3. EPS for the following year is $0.5, with 4 analysts recommending between $0.51 and $0.48.
Revenue Estimates
4 analysts predict $77.27M in revenue for the current quarter. It ranges from a high estimate of $79.7M to a low estimate of $76M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $56.91M, an estimated increase of 35.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $81.27M, an increase of 35.20% less than the figure of $35.80% in the same quarter last year. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $78.4M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $337M, while the lowest revenue estimate was $331.9M, resulting in an average revenue estimate of $333.87M. In the same quarter a year ago, actual revenue was $258.21M, up 29.30% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $389.87M in the next fiscal year. The high estimate is $395.5M and the low estimate is $383.5M. The average revenue growth estimate for next year is up 16.80% from the average revenue estimate for this year.
